ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2017
Minimal Residual Disease Negativity Is a New End Point of Myeloma Therapy.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06109233 (A Perspective Study of the MRD-tailored Therapy in Patients With Newly Diagnosed Multiple Myeloma With Persistent Minimal Residual Disease After Initial Treatment), which is not on this map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Perspective Study of the MRD-tailored Therapy in Patients With Newly Diagnosed Multiple Myeloma With Persistent Minimal Residual Disease After Initial Treatment
Who cites it
12 citing papers in PubMed.
- Trial
- Real-world evidence of measurable residual disease assessment in multiple myeloma.Blood advances · 2026Article
- Opportunities and challenges for MRD assessment in the clinical management of multiple myeloma.Nature reviews. Clinical oncology · 2025Review
- Multiple Myeloma in 2023 Ways: From Trials to Real Life.Current oncology (Toronto, Ont.) · 2023Review
- Use of Minimal Residual Disease Status to Reduce Uncertainty in Estimating Long-term Survival Outcomes for Newly Diagnosed Multiple Myeloma Patients.Journal of health economics and outcomes research · 2023Article
- Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis.Blood cancer journal · 2021Article
- Tumor Reduction in Multiple Myeloma: New Concepts for New Therapeutics.Frontiers in oncology · 2021Article
- Bortezomib, Lenalidomide and Dexamethasone as Induction Therapy Prior to Autologous Transplantation in Multiple Myeloma: The More Is Likely the Better.Clinical hematology international · 2020Article
- Minimal Residual Disease in Multiple Myeloma: Current Landscape and Future Applications With Immunotherapeutic Approaches.Frontiers in oncology · 2020Review
- [The prognostic significance of dynamic monitoring of minimal residual disease (MRD) status in patients with newly-diagnosed multiple myeloma].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2019Article
- Daratumumab for the treatment of AL amyloidosis.Leukemia & lymphoma · 2019Review
- Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives.Frontiers in oncology · 2019Review
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
28525304What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.